Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
-0.92 (-1.39%)
Real-time:   1:54PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 64.87 - 65.89
52 week 51.56 - 70.05
Open 65.58
Vol / Avg. 2.63M/7.38M
Mkt cap 106.41B
P/E 27.64
Div/yield 0.40/2.45
EPS 2.36
Shares 1.63B
Beta 0.98
Inst. own 73%
May 2, 2018
Bristol-Myers Squibb Co Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 26, 2018
Q1 2018 Bristol-Myers Squibb Co Earnings Call - 10:30AM EDT - Add to calendar
Apr 26, 2018
Q1 2018 Bristol-Myers Squibb Co Earnings Release - 9:30AM EDT - Add to calendar
Mar 14, 2018
Bristol-Myers Squibb Co at Barclays Global Healthcare Conference - Webcast
Mar 12, 2018
Bristol-Myers Squibb Co at Cowen Health care Conference - Webcast
Feb 15, 2018
Bristol-Myers Squibb Co at Leerink Partners Global Healthcare Conference - Webcast
Feb 14, 2018
Nektar Therapeutics and Bristol-Myers Squibb Announce Global Development and Commercialization Collaboration Conference Call - Webcast
Feb 5, 2018
Q4 2017 Bristol-Myers Squibb Co Earnings Release
Feb 5, 2018
Q4 2017 Bristol-Myers Squibb Co Earnings Call - Webcast
Jan 9, 2018
Bristol-Myers Squibb Co at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 10.41% 18.63%
Operating margin 14.02% 25.24%
EBITD margin - 36.45%
Return on average assets 6.74% 11.51%
Return on average equity 17.18% 27.96%
Employees 23,700 -
CDP Score - A-


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Officers and directors

Giovanni Caforio M.D. Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer and Executive Vice President - Global Business Operations
Age: 58
Bio & Compensation  - Reuters
Ann Powell Judge Chief Human Resource Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Thomas J. Lynch Jr., M.D., Ph.D. Executive Vice President, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Murdo Gordon Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Paul von Autenried Senior Vice President, Chief Information Officer
Age: 56
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Karen Santiago Senior Vice President, Controller
Age: 47
Bio & Compensation  - Reuters
John E. Elicker Senior Vice President - Corporate Affairs and Investor Relations
Age: 58
Bio & Compensation  - Reuters